(CYDY) announced an exclusive distribution and delivery agreement with American Regent for its Covid 19 leronlimab trial treatment in the United States. About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for several therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a crucial role in HIV`s ability to penetrate and infect healthy T cells. The CCR5 receptor also appears to be involved in tumor metastases and immune diseases such as GvHD and NASH. CytoDyn has completed a Phase 3 approval study of leronlimab in combination with standard antiretroviral therapy in HIV-infected patients with therapeutic experience. .